Search research articles
Contact Us
Filters
Showing results (551-560 of 703) with videos related to
Page
of 71
Sort By:
The Australasian Journal of Dermatology
|
April 29, 2022
Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study
Dale Jobson, Benjamin Roffey, Christopher Arnold, et al.
JAMA Network Open
|
June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders
Kylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 30, 2025
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
J S Deutsch, R A Scolyer, E Burton, et al.
Annals of Surgical Oncology
|
October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma
Elan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Nature Medicine
|
October 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial
Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Julie R Brahmer, Georgina V Long, Omid Hamid, et al.
The Lancet. Oncology
|
January 5, 2025
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
Axel Hauschild, Claus Garbe, Paolo Antonio Ascierto, et al.
Page
of 71
Search research articles
Search
Showing results (551-560 of 703) with videos related to
Sort By:
Page
of 71
The Australasian Journal of Dermatology
|
April 29, 2022
Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study
Dale Jobson, Benjamin Roffey, Christopher Arnold, et al.
JAMA Network Open
|
June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders
Kylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 30, 2025
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
J S Deutsch, R A Scolyer, E Burton, et al.
Annals of Surgical Oncology
|
October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma
Elan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Nature Medicine
|
October 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial
Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Julie R Brahmer, Georgina V Long, Omid Hamid, et al.
The Lancet. Oncology
|
January 5, 2025
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
Axel Hauschild, Claus Garbe, Paolo Antonio Ascierto, et al.
Page
of 71